ReviewJournal of pharmaceutical policy and practice2026
Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades.
Review in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Collaborating for Affordable Patient Access to Medicines: Review of the First Decade of the Beneluxa Initiative in Pharmaceutical Policy.Applied health economics and health policy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In 2005, the Pharmaceutical Pricing and Reimbursement Information (PPRI) network of public authorities was established to offer a platform for information exchange among authorities responsible for pharmaceutical pricing and reimbursement. The article reviews the evolution of PPRI over its twenty years of existence and aims to identify its contributions to policymakers and the research community as well as areas for future development. Methods: Based on a framework of structure, process and outcome indicators, adapted from the Donabedian Model, the article examines developments regarding membership in terms of geographic and thematic scope, governance, procedures for intra-network exchange of information as well as stakeholder engagement, and outcomes in terms of scientific output and spin-off activities. The review was informed by grey and peer-reviewed literature as well as unpublished information within the PPRI network. Results: The PPRI network has evolved from a European group into a global network, comprising approximately 80 public authorities in pharmaceutical pricing and reimbursement from 50 countries. Its thematic focus remains pricing and reimbursement policies, and additionally, the PPRI network addressed several related topics. In 2018, a sub-group on medical devices (PPRI MD) was established. PPRI mainly serves its members by facilitating informed discussion at face-to-face and online meetings, and through internal queries on timely and policy-related topics. PPRI-sourced data has been published, including country information such as PPRI Pharma Profiles and Briefs, and scientific studies based on cross-country analyses. PPRI conferences offer an opportunity for disseminating scientific output and engaging with stakeholders. Conclusion: PPRI is a network that has proven its value to policymakers by fostering information exchange as well as by producing reliable and relevant evidence. Success factors identified include a robust governance structure with clear responsibilities, a dedicated Secretariat as a coordinating function and the safe-space character of the network for its members.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.